Skip to main content
INSIGHT LIFETECH CO., LTD. logo

INSIGHT LIFETECH CO., LTD. — Investor Relations & Filings

Listed
Ticker · 688712 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 40 across all filing types
Latest filing 2026-06-05 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688712

About INSIGHT LIFETECH CO., LTD.

https://www.insight-med.com/

Insight Lifetech Co., Ltd. is a medical technology firm specializing in advanced interventional cardiology diagnostic solutions. The company focuses on the research, development, and manufacturing of intravascular imaging and physiological assessment systems designed to optimize the treatment of cardiovascular diseases. Its primary product portfolio includes high-resolution Intravascular Ultrasound (IVUS) systems, Optical Coherence Tomography (OCT) platforms, and Fractional Flow Reserve (FFR) measurement tools. A key innovation is the integration of anatomical imaging and functional assessment into unified platforms, facilitating more precise clinical decision-making during percutaneous coronary interventions. By providing high-precision catheters and sophisticated imaging consoles, the company supports clinicians in evaluating lesion morphology and hemodynamic significance to improve patient outcomes.

Recent filings

Filing Released Lang Actions
关于使用募集资金向控股子公司提供借款以实施募投项目的公告
Capital/Financing Update Classification · 75% confidence The document is a regulatory announcement by Shenzhen Beixin Life Technology Co., Ltd. regarding the use of IPO proceeds (“募集资金”) to provide a loan to its controlled subsidiary for project implementation. It details the board resolution, loan amount, interest rate, and use-of-proceeds supervision. This falls under “updates on company fundraising, financing activities, or capital structure changes” rather than a full financial report or audit, so it is classified as a Capital/Financing Update (CAP).
2026-06-05 Chinese
中国国际金融股份有限公司关于深圳北芯生命科技股份有限公司使用募集资金向控股子公司提供借款以实施募投项目的核查意见
Regulatory Filings Classification · 82% confidence The document is a sponsor (保荐人) verification opinion regarding the use of IPO proceeds by Shenzhen Beixin Life Science to provide a loan to its subsidiary. It contains regulatory references (e.g., listing rules, fundraising rules), but no standalone financial statements or management commentary that would qualify it as an Annual, Interim, or Audit Report. It is not a dividend, capital change, or share transaction announcement, nor an earnings release. Rather, it is a compliance filing under stock exchange and CSRC regulations about the use of raised funds. Therefore it falls under the broad "Regulatory Filings" category (RNS) as a specialized disclosure that does not fit other specific types.
2026-06-05 Chinese
中国国际金融股份有限公司关于深圳北芯生命科技股份有限公司使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的核查意见
Regulatory Filings Classification · 85% confidence The document is a sponsor (保荐人) verification opinion on Shenzhen Beixin Life Technology Co., Ltd.’s use of raised IPO proceeds to replace company-funded (self-raised) investments and issuance costs. It does not contain financial statements or constitute an Annual Report, Interim Report, Audit Report, or Earnings Release. It is a regulatory compliance opinion filed in connection with listing rules rather than substantive financial data or investor presentation. Therefore, it falls under the miscellaneous regulatory filing category (RNS).
2026-06-05 Chinese
关于使用闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 93% confidence The document is a routine securities exchange announcement (‘公告’) by Shenzhen Beixin Life Technology Co., Ltd. concerning the use of temporarily idle IPO proceeds for low-risk cash management products. It contains no financial statements, no change in board or management, no vote results, no dividends, share issues, or debt financing details. It is a compliance disclosure under stock exchange and CSRC rules. It therefore best fits the fallback category for general regulatory filings.
2026-06-05 Chinese
中国国际金融股份有限公司关于深圳北芯生命科技股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 85% confidence The document is an official “核查意见” (sponsor’s investigation opinion) by China International Capital Corp regarding Shenzhen Beixin Life Technology’s use of temporarily idle IPO proceeds for cash management. It is not an annual, interim or earnings report, nor a board change, proxy, voting, M&A or dividend notice. It does not present substantive financial statements or prospectus materials but rather a compliance/opinion letter under Shanghai Stock Exchange and CSRC rules. This falls under general regulatory filings (fallback category).
2026-06-05 Chinese
关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 85% confidence The document is an official board announcement by Shenzhen Beixin Life Science Technology Co., Ltd. detailing the use of IPO proceeds (“募集资金”) to replace earlier self-financed contributions to investment projects and issuance expenses. It is not the full financial report itself, nor is it merely a publication notice or certification, but a substantive update on how fundraising proceeds are being allocated. This fits squarely within “Capital/Financing Update” (CAP).
2026-06-05 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.